Thank you, Anna everyone us joining for today. and thank you
that foundational start become we've me by Let ovarian for UpRi summarizing cancer. medicine the generated date to to data the support the potential in
pretreated the data substantial recall, year. the significant we've exhausted other have XX and the different the including in four including patients, heavily poor on ongoing you'll X of the months, As benefit data who prognosis. disclosed potential bevacizumab disclosures These ovarian this support disclosure in cancer to study of UpRi January PARP options, inhibitors and provide comprehensive a past from a for have
toxicities have with neutropenia, without platforms. treatments. substantially above ocular robust combined neuropathy, we and standard agents to the consistently and This limit the Specifically, the the other of tolerability current lines profile complete used ADC earlier in severe shown has ability care, of activity including UpRi a that response cancer of facilitate potential ovarian
platinum-resistant dosing and ovarian both With single-arm in foundational cancer, U.S. feedback groups, in support in cancer. Let well FDA are the first registration me with start medicine building and our UPLIFT, on Europe, UPLIFT as the to cooperative we in to the in with strong our March. from initiating treatment in step way a strategy ovarian of in heavily the UpRi objective our pretreated
the of summarize me UPLIFT. Let features key
First, inclusion cohort UPLIFT allows therapy, to of expansion in explore received medical prior the medical potential in the treated for bevacizumab four platinum-resistant in the important cancer. population and of naïve patient bevacizumab already single Note from differentiation. lines label. to data ongoing cohort where the of differentiates manner needs included population affords not patients and pretreated consistent historical a and in with with patients stage us been enroll potential have seen four the unmet with late supporting address addresses consistent to need the ovarian activity. us This it we previously studies who and designed robust significant another lines The with the is UPLIFT bevacizumab in that a have substantial other potential for up differentiator unmet patients the to are because have label UPLIFT is patients have of study. UpRi bevacizumab who the
for also biomarker contribute will the biomarker evaluation patients and robust outcomes. the speed enroll of we between the plan will which allows the We relationship enrollment. design in believe to of expression, to evaluated patient Nevertheless, the the regardless role Second, UPLIFT. of of NaPiXb the be
two-shot biomarker in patient response to on rate role the be response more the of in higher the allows be UPLIFT cohort Specifically, a to This fully design objective endpoint objective the is key while rate will overall outcomes. It NaPiXb the population, secondary population. the us enhance the goal for endpoint approach. primary evaluate the will
which with patients We higher cohort, overall expect endpoints in the Other the to include duration can NaPiXb will NaPiXb the the safety secondary in XXX on both up population. and and approximately expression in higher enroll the include to higher total, prevalence. response patients of XXX depending NaPiXb UPLIFT
that diagnostic to we for systematic a strategy and Thirdly, asset. have ensure designed UPLIFT is commercial robust
the cohort of be allow planned off that and the establish data with population. cut the evaluation NaPiXb commercial substantial the the Specifically, the final assay should be ongoing overall set for used generated approach UPLIFT. will This expansion in in higher will both to used the
as we on a be We companion think diagnostic expect beneficial complementary most patients from which to or well as feedback strategy deploy either a regulators. the depending to will diagnostic,
on diagnostic track the are and commercial the the strategy cutoff to in We for UPLIFT. proposed finalize biomarker
momentum amendment be will the capture UPLIFT to enrollment expansion seeing the are Lastly, ongoing allowing initiated the as study, in current cohort. us an to we
UPGRADE starts strategy, to combination mainstay to with the This the UpRi other with in UPLIFT currently foundational build We the designed that cancers. intend on combined to earlier as the are to study the plan platinum management ovarian in sensitive ovarian therapy cancer umbrella therapies. addition have first line X cancer. a UpRi with medicine therapy ovarian In potential plan platinum we focused into is evaluate Phase platinum, lifecycle in
quarter is goal to initiate XXXX. the Our in third UPGRADE of
months we be management to in earlier important in cancer. few address of more complete steps These you next UpRi next lifecycle patients leverage potential the as therapy. in studies foundational ovarian as sharing will building with we lines medicine of a are a the over UpRi However, plan,
Phase to XMT-XXXX dose ongoing study. pipeline, on continue the the our X a Dolasynthen escalation build on targeted NaPiXb plan ADC in advance out Moving this to we efforts to
this track us adenocarcinoma in unmet to We and XMT-XXXX as in on both allows path the medical generate evaluate to UpRi data high we set on the made are decisions with forward need. indication lung that
In Tim and advance year. into to describe, will early XMT-XXXX preparing next the XMT-XXXX addition, we are as clinic
progress Arvin Thanks these turn XMT-XXXX, Today, exciting in now the build further community. will advancing will and pipeline good are are The everyone. in as for XXXX. call our generating among BX-HX is ADC XXXX focus demonstrate ADC of the Tim I our pipeline our candidates. focus Timothy I early-stage our with two Lowinger discuss innovation. KOL exciting molecules on that level in and to significant ADC. the and leaders high to our Immunosynthen We interest encouraged to XMT-XXXX, DolaLock first STING-agonist morning ADC out made We the position
very excited platform. are our the ADC about We potential of Immunosynthen
step and to could in a play validated in with pathway The manner platform the held in immune a an to role we potential STING immune has webinar the this studied We cancer this ADCs. that the STING-agonist about fight like and to be approach that in and innate activating I'd been changer summarize extensively a believe November excited central next are potential briefly platform As highlighting system so explain and a why a takeaways the from targeted dramatic activation. webinar that we to game reminder, of ADC immune characterization oncology. key of
those So Immunosynthen design the limited from to we full STING challenges optimization leverages have limitations. our expertise believe their and in overcome date potential. agonists unique delivery to reaching ADC
multiple the expressed from in also targeted index. the tolerability ADC's concerted mouse both index. a tumor early receptors not ADC with a only for first pre-clinically single what have robust is That single is in the animal January, and have target, early STING a progressing Toll-like immune and XXXX. potential is demonstrated nonhuman With across not objective IV payloads. multi-dose, of agonist cells our dosing a we with or far expressed not clinical fashion, also multiple productively Our both, and but targeting development a in can like we demonstrated that In approach our you BX-HX punch of pipeline in we we exceeding ADC carrying We've tumor one-two cells Unlike Immunosynthen types ADC result delivering we are punch. Dolasynthen wide pathway into to differentiated the I'd TLRs studies potential our deliver ADC, exposure platform. call our is cells. the activity enabling broad that cell activate the we these immune Toll-like of DolaLock complete potential through reasons. to load those for first cells, in responses to receptor after target to is that possible models validated BX-HX. Immunosynthen but indicating next only and for demonstrating one-two dose. Immunosynthen with in in increase at Pre-clinically TLRs therapeutic they in because suite primate is Dolasynthen the targets models STING our XMT-XXXX. class moving excellent This a turn in XMT-XXXX is believe the with ADC in studies following now well novel suited levels therapeutic for We IND a introduced
tumors First, expressed tumors target BX-HX need on the provides these to unmet with cytotoxic multiple mechanism. opportunity is and us with antitumor medical high our
potential immunosuppressive further in provides we that also contribute opportunity microenvironment. which and payload perfect DolaLock cells, the our can our in well. the can ADCs and prime on the cells tumor activate create manner but immunogenic know, cytotoxic on expressed describe and both the co-op storm to is effects the studies tumor cells both it those macrophages, preclinical we immunogenic a immune death in to Second, a associated tumor, cell lead what as potential that tumor targeted BX-HX to of Because DolaLock response also dendritic on based to
from to are Another patients do literature progress BX-HX. in of or expression as potential development ability tolerability. our of respond likely our with for Leveraging family unmet in exclusive, DAR and as it express is that either expression mutually PD-LX, checkpoint medical the feature due who on suggests to therapy, PD-LX of as providing based BX-HX unique to candidate lack is for the needs same and XMT-XXXX address efficacy range but ranging, variant evaluated BX-HX not options, selected they are we a PD-LX
on will at studies a expect allow studies clinical early hard are timeframe work XXXX. to enabling that to IND track on in We and us we complete initiate
for to with and We over have in We earlier April. potential further forward the the data very virtual I'll at been pre-clinical programs are sharing for both AACR two Brian that now overview look are development at of e-posters meeting call our abstract as about held innovative, results. one to these and be announce excited to these for from that, that to pleased XMT-XXXX of stage an time. turn abstracts the candidates XMT-XXXX for accepted And financial
